Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Revance Therapeutics (RVNC) Ownership Overview
2.01% Insiders
18.86% Mutual Funds
0.46% Other Institutional Investors
12.25% ETFs
68.88% Public Companies and Individual Investors
The ownership structure of Revance Therapeutics (RVNC) stock is a mix of institutional, retail, and individual investors. Approximately 31.57% of the company’s stock is owned by Institutional Investors, 2.01% is owned by Insiders, and 68.88% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Nov 19, 2024 | David Hollander Cmo & Global Therapeutics Lead | xxxxxxxxxxxxx | $16296 |
| Apr 17, 2024 | Erica Jordan Cco | xxxxxxxxxxxxx | $9090 |
| Mar 19, 2024 | Tobin Schilke Chief Financial Officer | xxxxxxxxxxxxx | $67436 |
| Mar 19, 2024 | Dwight Moxie Clo & Gc | xxxxxxxxxxxxx | $58276 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2024 | xxxxxxxxxxxxx | $220502 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $4141376 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5,193,257 | Institution | 11.51% | ― | |
| 2,146,347 | Institution | 4.76% | ― | |
| 1,791,214 | Institution | 3.97% | ― | |
| 1,079,115 | Institution | 2.39% | ― | |
| 941,385 | Institution | 2.09% | ― | |
| 797,953 | Institution | 1.77% | ― | |
| 600,000 | Institution | 1.33% | ― | |
| 592,192 | Institution | 1.31% | ― | |
| 487,311 | Institution | 1.08% | ― | |
| 1,107,848 | Insider | 1.06% | 3,644,820 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,146,347 | Institution | 4.76% | ― | |
| 1,791,214 | Institution | 3.97% | ― | |
| 1,079,115 | Institution | 2.39% | ― | |
| 941,385 | Institution | 2.09% | ― | |
| 592,192 | Institution | 1.31% | ― | |
| 487,311 | Institution | 1.08% | ― | |
| 328,686 | Institution | 0.73% | ― | |
| 301,517 | Institution | 0.67% | ― | |
| 245,000 | Institution | 0.54% | ― | |
| 203,151 | Institution | 0.45% | ― |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,969,310 | Institution | 2.84% | 10,719,209 | |
| 2,800,172 | Institution | 2.68% | 9,212,566 | |
| 1,338,573 | Institution | 1.28% | 4,832,249 | |
| 954,602 | Institution | 0.91% | 3,140,641 | |
| 609,495 | Institution | 0.58% | 2,005,239 | |
| 487,326 | Institution | 0.47% | 1,759,247 | |
| 434,022 | Institution | 0.42% | 1,427,932 | |
| 328,686 | Institution | 0.31% | 1,186,556 | |
| 298,868 | Institution | 0.29% | 1,510,641 | |
| 286,826 | Institution | 0.27% | 943,658 |
FAQ
Who Owns Revance Therapeutics (RVNC)?
According to the latest TipRanks data, approximately 0.46% of the company's stock is held by institutional investors, 2.01% is held by insiders, and 68.88% is held by retail investors.
What percentage of Revance Therapeutics (RVNC) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.46% of Revance Therapeutics (RVNC) stock is held by institutional investors.
What percentage of Revance Therapeutics (RVNC) stock is held by retail investors?
According to the latest TipRanks data, approximately 68.88% of Revance Therapeutics (RVNC) stock is held by retail investors.
Who owns the most shares of Revance Therapeutics (RVNC)?
Vanguard owns the most shares of Revance Therapeutics (RVNC).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.